OrbiMed’s Alkermes ALKS Stock Holding History

OrbiMed’s Portfolio ALKS Stock Details ALKS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-151,400	Closed	-$4.74M	–	128
2023 Q2	$4.74M	Buy	+151,400	New	+$4.58M	0.09%	104
2018 Q4	–	Sell	-145,000	Closed	-$6.15M	–	132
2018 Q3	$6.15M	Hold	145,000	–	–	0.07%	124
2018 Q2	$5.97M	Hold	145,000	–	–	0.07%	125
2018 Q1	$8.4M	Hold	145,000	–	–	0.1%	109
2017 Q4	$7.94M	Hold	145,000	–	–	0.1%	111
2017 Q3	$7.37M	Hold	145,000	–	–	0.07%	113
2017 Q2	$8.41M	Hold	145,000	–	–	0.09%	103
2017 Q1	$8.48M	Buy	+145,000	New	+$8.22M	0.1%	101
2016 Q3	–	Sell	-172,000	Closed	-$7.43M	–	141
2016 Q2	$7.43M	Buy	+172,000	New	+$7.1M	0.08%	103
2014 Q3	–	Sell	-433,300	Closed	-$21.8M	–	131
2014 Q2	$21.8M	Buy	+433,300	New	+$20M	0.26%	62

Other funds holding ALKS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HJGA

Hardman Johnston Global Advisors Stamford, Connecticut $2.85B AUM 35.77% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

OrbiMed's ALKS Position: Q3 2023 in Review

OrbiMed sold out of Alkermes (ALKS) in Q3 2023, closing a stake of 151,400 shares — an estimated $4.74M sold.

OrbiMed first reported a position in ALKS in Q2 2014 and held it in 10 quarters. The position peaked at $21.8M in Q2 2014. 307 funds tracked by Wall St. Rank hold ALKS as of Q3 2023.

OrbiMed reported no remaining Alkermes position as of Q3 2023 after selling out during the quarter.
OrbiMed sold 151,400 Alkermes shares in Q3 2023, an estimated $4.74M.
OrbiMed first reported a position in Alkermes in Q2 2014 and held it in 10 quarters.
OrbiMed's Alkermes position peaked at $21.8M in Q2 2014.
307 funds tracked by Wall St. Rank held Alkermes as of Q3 2023.

Based on OrbiMed's 13F filing for Q3 2023, filed 14 Nov 2023.